The possibility that SGLT2 inhibitors may also possess unexpected benefits against ventricular arrhythmias emerges from post-hoc analysis of the DAPA-HF trial (that included also non-diabetic subjects), showing a reduction in the outcome composed of ventricular arrhythmias, resuscitated cardiac arrest, or sudden death (49). The gene discussed is SLC5A2; the disease is hydrops fetalis.